http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114195676-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C243-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C243-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C243-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C243-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C241-02 |
| filingDate | 2021-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114195676-B |
| titleOfInvention | Bisarylhydrazine compounds and their adducts and their application in the preparation of antitumor drugs |
| abstract | The invention discloses a biaryl hydrazine compound and its adduct and application in the preparation of antitumor drugs. Benzyloxycarbonylglycylprolyl is added to the hydrazine group of the hydrazine compound. The anticancer activity of the biarylhydrazine compound of the present invention is better than that of the existing positive control drug procarbazine; its Z-GP adduct can significantly reduce the in vitro toxicity and in vivo toxicity to normal cells, and can be inhibited by FAP in vitro and in vivo -α enzyme specifically hydrolyzes the excised dipeptide moiety (Z-GP) to release the hydrazinolysis product; its Z-GP adduct can significantly inhibit tumor growth and reduce toxicity to non-target organs in tumor-bearing nude mice. |
| priorityDate | 2021-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 131.